Neuralink
Developing ultra-high bandwidth brain-computer interfaces to restore human autonomy and visual perception.
Company FactsPrivately Held
Sales Network & Latest Commercial Policies
Overview of countries and territories with commercial operations, direct retail footprint, and active purchase incentives.
Investigational Medical Device & Clinical Study Protocol. N1 Link is not a commercially retail-sold consumer product. Implantation access is exclusively conducted under approved FDA Investigational Device Exemption (IDE) clinical protocols.
Clinical participant enrollment actively conducted at premier neurological research hospitals in the United States and Canada (PRIME and CAN-PRIME studies). Pre-regulatory dialogues underway with UK and European health authorities.
Direct distribution, logistics clearance, and local service support.
Regional Presence & Key Countries Served
United States
Active CoverageCountries / Areas: United States (FDA IDE trial sites including Barrow Neurological Institute, Phoenix, Arizona)
Hubs & Infrastructure: FDA-cleared institutional review board (IRB) clinical research partner centers for quadriplegia participants
Canada
Active CoverageCountries / Areas: Canada (Health Canada authorized CAN-PRIME study)
Hubs & Infrastructure: University Health Network (UHN) / Toronto Western Hospital authorized surgical center
Latest Sales Policies, Promotions & Guarantees
Zero Cost for Enrolled Clinical Trial Participants
100% SponsoredAll neurosurgical procedures, R1 robotic insertions, N1 wireless hardware, post-operative clinical monitoring, and neuro-rehabilitation are 100% sponsored and funded by Neuralink.
Open Patient Registry Recruitment
Patient RegistryIndividuals residing in the United States and Canada with quadriplegia, paraplegia, vision loss, or ALS can register online via the official Neuralink Patient Registry for active and upcoming trials.
FDA Breakthrough Device Designation for Blindsight
FDA BreakthroughGranted expedited FDA review for the Blindsight visual cortical interface project, designed to bypass damaged ocular nerves and restore visual perception to the blind.
Customer Programs & Value-Added Services
Continuous Individualized Engineering Support
Dedicated neuro-engineering teams provide participants with custom control profiles, specialized assistive software integrations, and gaming/productivity interfaces.
Stock Information & Financial Profile
Market valuation, public stock ticker / private secondary status, ownership structure, and top institutional investors.
Privately held corporate entity
Private Medical Venture Capital
Latest market pricing assessment
Valuation Context & Market Standing
Valued in the $5B–$8B range following a $280M+ Series D venture round led by Founders Fund, with strong demand from life-science and neuro-technology institutional backers.
Elon Musk & Equity Ownership
Privately held and controlled by co-founder Elon Musk alongside neuroscientists, neurosurgeons, and venture capital partners.
Key Institutional Shareholders & Venture Partners
Primary Products & Key Projects
Factual summaries, categories, and technical parameters for Neuralink.
N1 Implant (Telepathy)
The N1 Implant contains 1,024 electrode channels distributed across 64 ultra-fine flexible threads inserted into the motor cortex. Charged wirelessly through the skin, the device streams neural intent to computers and mobile devices for digital autonomy.
Neuralink Blindsight
Blindsight is a specialized Neuralink implant designed to directly stimulate the visual cortex in the occipital lobe. By bypassing damaged optical nerves or eyes entirely, Blindsight aims to restore visual perception even in individuals who have lost both eyes or were born blind.
R1 Surgical Robot
Because Neuralink’s threads are thinner than human hair (5 to 50 microns), the R1 Surgical Robot uses micron-level optical head tracking, sub-millimeter optics, and automated needle mechanisms to thread electrodes into the cortex without severing micro-blood vessels.
Verified Updates for Neuralink
Neuralink Details Long-Term Stability Data for Second Participant "Alex": Zero Thread Retraction and Autonomous CAD Engineering
Neuralink reported clinical data for its second participant, Alex. Improved surgical depth prevented thread retraction across all 64 electrode threads. Alex navigates 3D modeling in Autodesk Fusion 360 to design 3D-printed parts directly via neural signals.
Neuralink Clinical Report Confirms Stable Performance & Precision Control in Second Patient "Alex"
Neuralink published an official clinical progress report detailing the successful implantation of its N1 Link brain-computer interface in second human trial participant, Alex. Leveraging surgical mitigations that prevented thread retraction, Alex established high-speed digital cursor control in under 5 minutes, demonstrating competitive gameplay in Counter-Strike 2 and designing custom 3D CAD models in Fusion 360.
Neuralink Granted FDA Breakthrough Designation for Blindsight
Neuralink received FDA Breakthrough Device designation for "Blindsight", its visual cortex brain implant engineered to restore sight even for individuals who have lost both eyes.
Neuralink N1 Implant Demonstrates Rapid Cursor Control in Second Patient
Neuralink confirmed the successful surgical placement of its N1 BCI implant in a second human trial participant, who demonstrated digital cursor and gaming control.